title: Multiplex bead assay for serum samples from children in Haiti enrolled in a drug study for the treatment of lymphatic filariasis.
abstract: A multiplex bead assay (MBA) was used to analyze serum samples collected longitudinally from children enrolled in a drug trial for treatment of filariasis in Leogane, Haiti. Recombinant antigens Bm14 and Bm33 from Brugia malayi, third polar tube protein (PTP3) from Encephalitozoon cuniculi, and merozoite surface protein-1(19) (MSP-1(19)) from Plasmodium falciparum were coupled to carboxylated polystyrene microspheres. IgG responses to PTP3 and MSP-1(19) were not affected by albendazole (ALB), diethylcarbamazine (DEC), or combination of diethylcarbamazine and albendazole (DEC/ALB). However, IgG and IgG4 responses to Bm14 and Bm33 were significantly decreased (P < 0.001) by DEC and DEC/ALB treatment. Antibody responses to Bm14 and Bm33 decreased after DEC treatment (but not placebo) among children who were negative for microfilaremia and antigenemia at baseline, suggesting that these children harbored early stages of infection. The MBA is an excellent serologic technique for multiple antigens that offers substantial advantages over single-antigen based enzyme-linked immunosorbent assay in mass drug administration studies for monitoring changes in antibody levels.
authors.affiliation: National Center for Zoonotic, Vector-borne, and Enteric Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. dmm3@cdc.gov
authors.forename: Delynn M
authors.initials: DM
authors.lastname: Moss
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Priest
authors.forename: Alexis
authors.initials: A
authors.lastname: Boyd
authors.forename: Tiffany
authors.initials: T
authors.lastname: Weinkopff
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Kucerova
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Beach
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Lammie
mesh_terms: D000871:Anthelmintics / Q000008:administration & dosage / Q000627:therapeutic use; D000909:Antibodies, Helminth; D000947:Antigens, Helminth; D002648:Child; D002675:Child, Preschool; D004049:Diethylcarbamazine / Q000008:administration & dosage / Q000627:therapeutic use; D004605:Elephantiasis, Filarial / Q000097:blood* / Q000188:drug therapy / Q000453:epidemiology*; D006205:Haiti / Q000453:epidemiology; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D007074:Immunoglobulin G / Q000097:blood; D007559:Ivermectin / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000871:Anthelmintics; D000909:Antibodies, Helminth; D000947:Antigens, Helminth; D007074:Immunoglobulin G; D007559:Ivermectin; D004049:Diethylcarbamazine